Achilles Therapeutics plc

DUBLIN--( BUSINESS WIRE )--The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR-T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. Make investment decisions and valuations with confidence using the latest data. This report explores the opportunity in this market and what companies are poised to benefit. Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 1.2 Guide for Executives and Marketing Staff 1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition 2.1 What is Cancer Immunotherapy? 2.2 Immunotherapy - the looming cures 2.3 Market Definition 2.4 Methodology 2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective 2.5.1 Global Expenditures for Medicines 3 Immunotherapy - Guide to Immune Technologies 3.1 The Immune System 3.1.1 Innate immune system 3.1.2 Adaptive immune system 3.1.3 Tumor immunology - the immune surveillance system 3.2 Immuno Oncology Technologies 3.2.1 Monoclonal Antibodies 3.2.2 Cancer vaccines 3.2.3 Cytokines 3.2.4 Cell Based Therapies 3.2.5 Inhibitors/Agonists 3.2.6 Antibody Drug Conjugates 3.2.7 Others 4 Industry Overview 4.1 Market Players - Roles & Impacts 4.1.1 Drug manufacturers - Larger/pharmaceutical 4.1.2 Drug manufacturers - Generic 4.1.3 Contract Research and Manufacturing 4.1.4 In Vitro Diagnostics Industry 4.1.5 Drug Marketing Companies 4.1.6 Biotechnology Companies 4.1.7 Regulatory Bodies 5 Market Trends 5.1 Factors Driving Growth 5.1.1 Outcome potential 5.1.2 Fast tracking 5.1.3 Funding 5.1.4 Technology Environment 5.1.5 Target Solutions 5.2 Factors Limiting Growth 5.2.1 Cost of Treatment 5.2.2 Clinical Trials Role 5.2.3 Combinations 5.2.4 Protocols 5.3 Therapeutic Technology Development 5.3.1 Combinations - Issues and Complexity 5.3.2 Preference for a drug 5.3.3 Problems of Immunity Engineering 5.3.4 The Role of Cost 5.3.5 The Disruption Dynamic 5.3.6 CAR-T Cell Therapy 5.3.7 The Next Five Years 6 Cancer Immunotherapy Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.2 Continued Success with Immunotherapy in Melanoma 6.3 AC Immune Receives FDA Fast Track Designation 6.4 LTZ Announces Financing 6.5 Immunotherapy for Cancer Overview 6.6 Implantable device shrinks pancreatic tumors 6.7 mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence 6.8 Towards a Universal Cancer Immunotherapy 6.9 New Strategy May Improve T-Cell Therapy in Solid Tumors 6.10 Immunotherapy linked to increase in Medicare spending 6.11 Immunotherapy Effective with Ovarian Cancer 6.12 Cancer Immunotherapy Granted Fast Track 7 Profiles of Key Immunotherapy Companies AbbVie Achilles Therapeutics Acumen Pharmaceuticals Adagene Adaptimmune Therapeutics Adicet Bio ALX Oncology Holdings Ambrx Biopharma Amgen Apexigen Arcus Biosciences argenx AstraZeneca Atreca Avalo Therapeutics Avid Bioservices Bavarian Nordic BioAtla Biogen Inc. BioNTech Bolt Biotherapeutics Bristol-Myers Squibb Candel Therapeutics Caribou Biosciences Celldex Therapeutics Checkpoint Therapeutics Chinook Therapeutics Corvus Pharmaceuticals Cullinan Oncology Eli Lilly EOM Pharmaceuticals Evaxion Biotech Genenta Science Gilead Sciences Gracell Biotechnologies Greenwich LifeSciences Gritstone bio Harpoon Therapeutics ImmunityBio Immunocore Holdings Immunome IMV Inc Incyte Indaptus Therapeutics Instil Bio Iovance Biotherapeutics Johnson & Johnson Marker Therapeutics Medicenna Therapeutics Merck & Co. Merus Moderna Mustang Bio Nanobiotix Neoleukin Therapeutics Novartis Novavax Oncorus PDS Biotechnology Pfizer Regeneron Pharmaceuticals Roche Sanofi Sensei Biotherapeutics Senti Biosciences Surface Oncology Takeda Pharmaceutical TC Biopharm ThermoGenesis Holdings UroGen Pharma Werewolf Therapeutics Xilio Therapeutics Zymeworks 8 The Global Market for Immuno-Oncology Therapeutics 8.1 Global Market Overview by Country 8.2 Global Market by Therapy 8.3 Global Market by Cancer 8.4 Global Market by Customer 9 Global Immuno-Oncology Therapy Markets - By Therapy 9.1 MAB 9.2 Cytokine 9.3 Vaccine 9.4 Cell Based 9.5 Inhibitor/Agonist 9.6 Other IO Therapy 10 Global Immuno-Oncology Therapeutic Markets - By Cancer 10.1 Breast 10.2 ColoRectal 10.3 Cervical 10.4 Lung 10.5 Precancer 10.6 Prostate 10.7 Melanoma 10.8 Blood 10.9 Other Cancer 11 Global Immuno-Oncology Therapeutic Markets - By Customer 11.1 Pharma 11.2 Clinic 11.3 Other Customer For more information about this report visit https://www.researchandmarkets.com/r/8355qg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Achilles Therapeutics has engaged BofA Securities to explore and review “value-maximizing strategies.” Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, looking into deals with groups working on other modalities and preparing to lay off staff.London-based Achilles sounded committed to its tumor-infiltrating lymphocyte (TIL)-based therapy when it published updated phase 1/2 data one month ago. While there were no new objective responses, the biotech said the results showed the potential of its platform and identified the release of updated data with enhanced host conditioning as a milestone for the second half of 2024.Weeks later, Achilles has decided to stop development of its TIL-based therapy and close two phase 1/2a trials. CEO Iraj Ali, Ph.D., said the “studies in lung cancer and melanoma have not met our goals for commercial viability.”The biotech is planning to lay off people in conjunction with the R&D rethink. Achilles ended last year with 204 full-time employees plus 11 part-time staffers. A workforce reduction and other cost-cutting measures are in the works, but the details are still taking shape as part of an employee consultation process that Achilles is conducting in line with U.K. legislation. The future of the biotech is similarly uncertain. Achilles said it will “refocus its strategy to explore further engagement with third parties who are developing alternative modalities to target clonal neoantigens for the treatment of cancers, such as neoantigen vaccines, ADCs and TCR-T therapies.” The biotech has also engaged BofA Securities to explore and review “value-maximizing strategies.”Closing the two phase 1/2a trials eliminates Achilles’ clinical-phase pipeline, but the company still has assets that could be of interest to other drug developers. Arcturus Therapeutics entered into a research pact with Achilles in May. The mRNA specialist is developing vaccines that target clonal neoantigens, protein markers that Achilles can identify using its PELEUS bioinformatics platform.The biotech also has a Nasdaq listing and, as of the end of June, $95.1 million, assets that could support a reverse merger with a company that wants to list its shares and strengthen its bank balance without taking the IPO route. Achilles said a range of options, including a reverse merger, are on the table. 

Plus, news about GSK, Novo Nordisk, Tanai Therapeutics, Nomic Bio, Brenus Pharma, Xspray, Achilles Therapeutics, BioXcel Therapeutics and Nuvalent: Ascendis’ $300M offering: The Danish company announced the proposed share sale a few days after disclosing pivotal trial data for its dwarfism drug. — Kyle LaHucik Basilea secures anti-infectives deal with BARDA: The Swiss drugmaker will get $29 million in initial funding from the federal agency to advance development of two antifungal drugs, fosmanogepix and BAL2062. Basilea is eligible for up to $268 million in support under the terms of the multi-year agreement . — Ayisha Sharma GSK chips in with cash for antibiotic resistance organization: The $66 million in new funds will help the Global Antibiotic Research and Development Partnership speed up research into treatments for antibiotic-resistant infections. The UK drugmaker contributed €4.5 million, while the European Commission pledged €20 million. — Ayisha Sharma Novo Nordisk backs Belgian obesity startup: The Wegovy maker and BioGeneration Ventures are among the investors in Tanai Therapeutics’ €6 million seed round. — Kyle LaHucik Nomic Bio’s $42M Series B: The “protein profiling company” raised the money from Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures, and SR One. — Kyle LaHucik Brenus Pharma’s $25M round: Angelor, Noshaq and Investsud, among others, invested in the French startup’s Series A to support development of its cancer vaccine. — Kyle LaHucik Xspray Pharma to refile cancer drug with the FDA : The Stockholm-based biotech plans to resubmit Dasynoc for the second time in the fourth quarter, with an eye to a potential launch early next year. Xspray’s original NDA was hit with a CRL last year, and the FDA had requested more information related to dosing and a third-party manufacturer. — Ayisha Sharma Achilles Therapeutics undergoes strategic review: The company is stopping work on its TIL-based cNeT program. It is also planning a workforce reduction and other cost-cutting as it explores “new opportunities” for its assets. Its stock $ACHL was up about 30% on Thursday morning. — Jaimy Lee BioXcel Therapeutics is “ deprioritizing sales efforts” for Igalmi, its agitation treatment. — Jaimy Lee Nuvalent ended up raising a total of $575 million in its offering. — Jaimy Lee